hi guys

Hi everyone

After being out of EMS for probably 12 months I have re-entered over the last week or so.

With 765m fully diluted shares on issue, at a 2.2c share price a valuation of around $16m seems very cheap for a company with a phase 3 trial almost completed and sets up a good risk reward play over the next few months.

Hopefully we hear in the preliminary report that Ghana patient dosing has commenced, as the completion of this leg would give us the 150 patients required for the trial.

Onwards and upwards, and IMO people will return to the stock as we progress towards the trial completion.